Form 4: Decheng entities report mid‑Sept 2025 sales in BeyondSpring (BYSI)
Rhea-AI Filing Summary
Insider sales by Decheng-affiliated funds in BeyondSpring (BYSI) The filing shows Decheng Capital entities and Dr. Xiangmin Cui reported a series of open-market dispositions of BeyondSpring ordinary shares in mid-September 2025. Decheng Capital China Life Sciences USD Fund III, L.P. sold a total of 4,110 shares across trades on 09/12/2025, 09/15/2025 and 09/16/2025 at weighted-average prices reported as $1.85, $1.84 and $1.88 respectively. After those sales, Fund III’s reported beneficial ownership was 1,870,600 shares. The filing also reports indirect beneficial ownership of 1,617,409 shares by Decheng Capital China Life Sciences USD Fund II, L.P. and 891,734 shares by Decheng Capital Global Healthcare Fund (Master), LP. Signatures indicate Dr. Xiangmin Cui as manager executing the filing on behalf of the Decheng entities on 09/16/2025.
Positive
- None.
Negative
- Insider dispositions: Decheng Capital China Life Sciences USD Fund III sold 4,110 shares on 09/12–09/16/2025 at weighted-average prices reported around $1.84–$1.88.
- Concentration of ownership: Significant indirect holdings remain: 1,870,600 (Fund III), 1,617,409 (Fund II), and 891,734 (Global Healthcare), indicating continued insider exposure despite sales.
Insights
TL;DR: Decheng-related funds executed small open-market sales in mid-September 2025; material ownership remains concentrated across Decheng vehicles.
The Form 4 documents routine dispositions by Decheng Capital China Life Sciences USD Fund III totaling 4,110 shares across three trade dates with weighted-average prices disclosed in footnotes. The filing clarifies the chain of indirect beneficial ownership: Fund III, Fund II and the Global Healthcare master fund hold sizable indirect positions of 1,870,600; 1,617,409; and 891,734 shares respectively. All filings are executed by Decheng management and signed by Xiangmin Cui. From an investor-materiality perspective, these are disclosures of insider sales rather than corporate events; the filing does not report derivative transactions, changes to board composition, or financings.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Ordinary Shares | 840 | $1.88 | $2K |
| Sale | Ordinary Shares | 2,570 | $1.84 | $5K |
| Sale | Ordinary Shares | 700 | $1.85 | $1K |
| holding | Ordinary Shares | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Footnotes (1)
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.83 to $1.87 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.77 to $1.87 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.86 to $1.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. These securities are held directly by Decheng Capital China Life Sciences USD Fund II, L.P. ("Fund II"). Decheng Capital Management II (Cayman), LLC ("GP II") is the general partner of Fund II. Dr. Cui is the manager of GP II. Each of Fund II, GP II and Dr. Cui may be deemed to beneficially own the securities held by Fund II. Each of GP II and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Dr. Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein.
